Beta-Cell Replacement: Pancreas and Islet Cell Transplantation

Area of Science:

• Endocrinology
• Transplantation Surgery
• Immunology

Background:

• Type 1 diabetes mellitus (T1DM) necessitates beta-cell replacement therapies.
• Pancreas transplantation, since 1966, has evolved with improved surgical techniques and immunosuppression.
• Islet transplantation emerged as a less invasive alternative, with outcomes significantly improving since the Edmonton protocol in 2000.

Purpose of the Study:

• To compare pancreas and islet transplantation as beta-cell replacement therapies for T1DM.
• To highlight the advancements and current status of both procedures.
• To discuss their complementary roles in patient care and organ donor utilization.

Main Methods:

• Review of historical data and advancements in pancreas transplantation.
• Analysis of outcomes and evolution of islet transplantation protocols, including the Edmonton protocol.
• Comparative assessment of therapeutic efficacy, invasiveness, and patient selection criteria.

Main Results:

• Pancreas transplantation, often combined with kidney transplantation, shows high success rates but involves significant surgical morbidity.
• Islet transplantation, while initially having poor outcomes, now approaches whole pancreas transplant efficacy with less invasiveness.
• Both therapies effectively abolish hypoglycemia and can prevent or slow diabetes complications.

Conclusions:

• Pancreas and islet transplantation are complementary, not competing, therapeutic options for T1DM.
• These procedures offer significant benefits in managing diabetes and its complications.
• Optimizing organ donor use and patient care can be achieved by considering both transplantation approaches.